Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
GOVT iShares U.S. Treasury Bond ETF
BAC Bank of America Corp
$NQASPA50JPYN Nasdaq ASPA Industrials Net Total Re
SNP China Petroleum & Chemical Corp
GAEC Gulf Alternative Energy Corp
RDBX Redbox Entertainment Inc
AFG American Financial Group Inc
MRNA Moderna Inc
PFE Pfizer Inc
Go

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Closing Price
$25.00
Day's Change
-2.70 (-9.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
27.48
Day's Low
25.00
Volume
(Average)
Volume:
41,633

10-day average volume:
46,038
41,633

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.